New APVO436 Preclinical Data Show Robust T-Cell Engagement and Cytotoxicity in AML Patient Specimens
Anticipates 2 IND Filings in 2018 for Novel Bispecific Antibody Candidates
Strengthened Cash Position to Support Ongoing R&D and Commercial Activities;
Emergent's (EBS) earnings and revenues beat estimates in Q3. Revenues also rise year over year on higher product sales and increase in contract manufacturing revenues.
New Preclinical Data Show APVO436 Demonstrates Rapid and Significant Reduction in Skeletal Tumor Burden in Mice with Well-Established and Disseminated Tumors
LUND, Sweden and SEATTLE, Washington, October 24, 2017 /PRNewswire/ --
ALG.APV-527 Engineered to Engage the Immune System for the Potential Treatment of Multiple Solid Tumor Indications
New Autoimmune Candidate APVO210 Demonstrates Targeted Cytokine Delivery for Application in Various Autoimmune and Inflammatory Diseases
NEW YORK, NY / ACCESSWIRE / October 10, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive...
PALM BEACH, Florida, October 6, 2017 /PRNewswire/ --
Oppenheimer's Leah Rush Cann recently published an article on Barron's writing Biotech stocks, that still remain sharply undervalued, with an optimistic outlook that comes on the heels of the biotech sector...
Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, today announced that new information on the Company's proprietary...
Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, today announced that it has amended the terms of a credit agreement...
Sharpens Focus on Innovative ADAPTIR Bispecific Antibody Platform and IXINITY Commercial Asset
Provides Significant Non-Dilutive Funding to Execute R&D Strategy
Aptevo Regains Worldwide Rights to Novel Bispecific Prostate Cancer Immunotherapeutic MOR209/ES414
Novel Bispecific Antibody Targeting Biological Pathway Implicated in Multiple Solid Tumor Indications
Emergent's (EBS) earnings and revenues miss estimates in Q2. However, revenue increased year-over-year due to product sales and increase in contract manufacturing revenues.
Strategic Partnership Will Advance Development of a Novel Bispecific
Expands ADAPTIR Portfolio and Announces New Bispecific Candidate; Presents Data at the